Searchable abstracts of presentations at key conferences in endocrinology

ea0034oc3.1 | Steroids | SFEBES2014

Lack of 11β-hydroxysteroid dehydrogenase type 1 ameliorates the adverse features of Cushing's syndrome

Morgan Stuart , McCabe Emma , Gathercole Laura , Hassan-Smith Zaki , Larner Dean , Bujalska Iwona , Stewart Paul , Tominson Jeremy , Lavery Gareth

Glucocorticoids are widely prescribed for their anti-inflammatory properties, but have a significant adverse effect profile, leading to a Cushingoid phenotype. In the present study, we test the hypothesis that reactivation of glucocorticoids, in peripheral tissues by 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), is a major determinant of exogenous Cushing’s syndrome.WT, global 11β-HSD1 knockout (GKO), liver-specific 11β-HSD...